• Welcome, Guest. Please login or register.
    April 05, 2020, 08:19:06 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:


Click to visit us on Facebook

If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Thalassemia Patients and Friends and thalpal Ā© A. Battaglia 2019

55248 Posts in 5898 Topics by 6188 Members
Latest Member: jcemanuele

Forum Tip: 
Put your birthdate in your profile, under "Forum Profile Information," and it will automatically come up on our calendar.
« previous next »
Pages: 1 Go Down Print
Author Topic: HDAC6 inhibition  (Read 4360 times)
Junior Member
Offline Offline

Posts: 132

« on: December 30, 2012, 08:12:42 PM »

Acetylon's HDAC drug fights sickle cell disease, beta thalassemia in blood cell studies
December 18, 2012 | By Suzanne Elvidge

In a preclinical study in human blood cells, Acetylon Pharmaceuticals' selective histone deacetylase (HDAC) 1/2 inhibitor was able to trigger production of fetal hemoglobin, a working form of hemoglobin that is suppressed in adults. This could lead to a treatment for sickle cell disease and beta thalassemia, both diseases in need of safer and more effective treatments. The results were presented at the 54th annual meeting of the American Society of Hematology (ASH). HDACs are members of a group of enzymes that help regulate gene expression. Acetylon's lead drug, the HDAC6 inhibitor ACY-1215, is in a U.S.-based Phase I/II study for the treatment of multiple myeloma, funded by a $27 million round of venture cash raised in 2011, and a $15 million strategic investment from Celgene in 2012. Other companies working on HDAC inhibitors include MEI Pharma ($MEIP) and 4SC, and gene therapy can flip the switch to produce fetal hemoglobin.
Global Moderator
Supreme Member
Offline Offline

Location: Canada

Gender: Female
Posts: 4155

Little A

« Reply #1 on: December 30, 2012, 08:47:42 PM »


This seems great - what are your thoughts on this research?

Active Member
Offline Offline

Posts: 39

« Reply #2 on: January 01, 2013, 09:56:01 AM »

One more ray of hope...
Andy Battaglia
Supreme Member
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8636

Will thal rule you or will you rule thal?

« Reply #3 on: January 01, 2013, 04:02:52 PM »

This drug's actions are similar to the short chain fatty acid drugs currently being developed, such as HQK-1001. However, this drug is more focused and fewer side effects are a main goal.

There are many different approaches being studied for treating thalassemia. I wish the efforts were coordinated and well financed.


All we are saying is give thals a chance.
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!